Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.38 |
| ▸ | F2 | P00734 | 4/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | F7 | P08709 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27579761 | 0.89 | F10 (0.43) | F10ITGB3ITGA2BPOLBPRSS1 | |
| SCHEMBL6779135 | 0.82 | TSHR (0.44) | F10ITGB3ITGA2BPOLBPRSS1 | |
| SCHEMBL6784570 | 0.81 | F10 (0.49) | F10PRSS1F2 | |
| SCHEMBL6783740 | 0.80 | ENPP2 (0.46) | F10ITGB3ITGA2BPRSS1MEN1 | |
| SCHEMBL6777481 | 0.80 | ITGB3 (0.41) | F10ITGB3ITGA2BPOLBPRSS1 | |
| SCHEMBL6777513 | 0.79 | F10 (0.45) | F10ITGB3ITGA2BPOLBPRSS1 | |
| SCHEMBL6779880 | 0.79 | MAPT (0.44) | F10PRSS1F2F7MEN1 | |
| SCHEMBL6780280 | 0.76 | LMNA (0.47) | F10POLBPRSS1F2F7 | |
| SCHEMBL6779499 | 0.76 | SLC28A3 (0.35) | F10L3MBTL1 | |
| SCHEMBL6775750 | 0.74 | MAPT (0.51) | F10POLBPRSS1F2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794507-B2 | Compounds that inhibit factor Xa activity | MORPHOCHEM AG (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20030153510-A1 | Novel compounds inhibiting factor xa activity | CAPPI MICHAEL W (DE) | 2003-08-14 | — | — | US | disclosed |
| EP-1311473-A2 | NOVEL COMPOUNDS INHIBITING FACTOR XA ACTIVITY | Morphochem AG (DE) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016312-A2 | NOVEL COMPOUNDS INHIBITING FACTOR XA ACTIVITY | MORPHOCHEM AG (DE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153510-A1 | Novel compounds inhibiting factor xa activity | SERPINC1, F11, TFPI | F10 6/4885ITGB3 2055/4885ITGA2B 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.